Gastrointestinal Cancer | Specialty

Expert Discusses CRC Developments, Importance of Molecular Profiling

February 4th 2019

Pashtoon M. Kasi, MD, MBBS, MS, provides an overview of the potential for liquid biopsies in CRC and advances being made in the treatment landscape.

Expert Highlights Ongoing Research Efforts in HCC, NETs

February 1st 2019

Daneng Li, MD, shed light on some of the currently available regimens and ongoing research efforts being conducted in hepatocellular carcinoma and neuroendocrine tumors.

Overcoming Acquired Resistance Mechanisms in BRAF+ mCRC

January 31st 2019

First-Line Triplet in BRAF+ mCRC

January 31st 2019

Real-World Management of Patients with BRAF-V600E mCRC

January 31st 2019

CRC Safety Lead-in: ASCO GI 2019 Updates

January 31st 2019

Combining BRAF, MEK and EGFR Inhibition in mCRC

January 31st 2019

Lack of Durable Responses in Current Treatment of mCRC

January 31st 2019

Sequencing Strategies in BRAF-Mutated mCRC

January 31st 2019

Prognosticating BRAF-Mutant mCRC

January 31st 2019

Dr. Chao on Practice-Changing Data in Metastatic Gastroesophageal Cancer

January 31st 2019

Joseph Chao, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses practice-changing data in metastatic gastroesophageal (GEJ) cancer.

Dr. Fakih on Durvalumab and Tremelimumab in CRC

January 31st 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the combination of durvalumab (Imfinzi) and tremelimumab in patients with metastatic colorectal cancer (mCRC).

Dr. Chung on Sequencing Chemotherapy Regimens in Metastatic Pancreatic Cancer

January 31st 2019

Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, Director Phase I Program, City of Hope, discusses sequencing chemotherapy regimens in patients with metastatic pancreatic cancer.

SM-88 Shows Promise in Advanced Pancreatic Cancer

January 31st 2019

Allyson J. Ocean, MD, discusses the potential impact of SM-88 in the treatment of patients with advanced pancreatic cancer and highlights a platform that patients can use to stay updated on the latest research in the field.

Dougan Discusses Augmenting T-Cell Activity in Pancreatic Cancer

January 29th 2019

Stephanie K. Dougan, PhD, discusses research aimed at assessing ways of augmenting T-cell immunity in pancreatic cancer.

Dr. Picozzi on the Use of SM-88 in Pancreatic Cancer

January 29th 2019

Vincent J. Picozzi, MD, director, Pancreatic Center of Excellence, Virginia Mason Medical Center, discusses the use of SM-88 in pancreatic cancer.

Immune-Oncology Role Continues to Be Refined in GI Cancer

January 28th 2019

Michael J. Overman, MD, highlights new combination agents under investigation for the treatment of patients with GI cancers—specifically CRC—and challenges that still need to be addressed.

Radiation Could Aid in Increasing Pancreatic Cancer Resections

January 28th 2019

Amol K. Narang, MD, discusses recent advances made in the treatment of pancreatic cancer and explained how radiation oncology can be used to provide further clinical benefit to this patient population.

Dr. Shields Discusses Patient Selection Criteria for Adjuvant Therapy in CRC

January 25th 2019

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses patient selection criteria for adjuvant therapy in colorectal cancer (CRC).

Dr. Kasi on the Rising Incidence of CRC

January 24th 2019

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses the rising incidence of colorectal cancer (CRC).